Clinical efficacy of debulking surgery combined with targeted therapy in metastatic kidney cancer
Objective To investigate the clinical efficacy of debulking surgery combined with targeted therapy in metastatic renal cancer based on clinical practice experience.Methods A total of 118 cases of metastatic kidney cancer admitted to the Second Affiliated Hospital of the University of South China from October 2019 to May 2022 were enrolled,and they were divided into two groups according to the treatment methods,60 cases in the control group were treated by debulking surgery,58 cases in the observation group were treated with debulking surgery,and postoperative combined with targeted therapy were compared to compare the dis-ease control rate and objective remission rate of the two groups,and the renal function level and immune func-tion level of the two groups before and after treatment were compared,and the complications of the two groups were observed.Results The disease control rate(79.31%)in the observation group was significantly higher than that in the control group(56.90%),and the difference was statistically significant(χ2=7.671,P=0.006).The objective response rate of patients in the observation group(56.90%)was significantly higher than that in the control group(39.66%)(χ2=4.989,P=0.026).There was no significant difference in renal function between the two groups before treatment(P>0.05).After treatment,the levels of serum creatinine(Scr),urea nitrogen(BUN)and 24-hour urinary protein quantification(Upro)in the observation group were lower than those in the control group(P<0.05).After treatment,the levels of immunoglobulin A(IgA),bovine immuno-globulin G(IgG)and immunoglobulin M(IgM)in the observation group were higher than those in the control group(P<0.05).The complication rate of patients in the observation group(5.17%)was significantly lower than that in the control group(6.90%),but the difference was not statistically significant(χ2=0.152,P=0.697).Conclusion Tumor reducing surgery combined with targeted therapy has significant clinical efficacy in meta-static kidney cancer,which can improve the level of renal function and immune function in patients without in-creasing complications,and has a high safety profile.
万方数据
维普
